Advertisement

Topics

CRO Appointed To Conduct Trial Of Biondvax's Universal Flu Vaccine

05:00 EDT 14 Mar 2018 | Pharmaceutical Processing

BiondVax Pharmaceuticals Ltd. developer of the Universal Flu Vaccine candidate M-001 has selected a CRO to conduct the Phase 3 Trial.
Contributed Author: 
BiondVax Pharmaceuticals Ltd.

Original Article: CRO Appointed To Conduct Trial Of Biondvax's Universal Flu Vaccine

NEXT ARTICLE

More From BioPortfolio on "CRO Appointed To Conduct Trial Of Biondvax's Universal Flu Vaccine"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...